186 related articles for article (PubMed ID: 29786170)
1. Immunopeptidomic Profiling of HLA-A2-Positive Triple Negative Breast Cancer Identifies Potential Immunotherapy Target Antigens.
Ternette N; Olde Nordkamp MJM; Müller J; Anderson AP; Nicastri A; Hill AVS; Kessler BM; Li D
Proteomics; 2018 Jun; 18(12):e1700465. PubMed ID: 29786170
[TBL] [Abstract][Full Text] [Related]
2. CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer.
Paret C; Simon P; Vormbrock K; Bender C; Kölsch A; Breitkreuz A; Yildiz Ö; Omokoko T; Hubich-Rau S; Hartmann C; Häcker S; Wagner M; Roldan DB; Selmi A; Türeci Ö; Sahin U
Oncotarget; 2015 Sep; 6(28):25356-67. PubMed ID: 26327325
[TBL] [Abstract][Full Text] [Related]
3. IFNγ Modulates the Immunopeptidome of Triple Negative Breast Cancer Cells by Enhancing and Diversifying Antigen Processing and Presentation.
Goncalves G; Mullan KA; Duscharla D; Ayala R; Croft NP; Faridi P; Purcell AW
Front Immunol; 2021; 12():645770. PubMed ID: 33968037
[TBL] [Abstract][Full Text] [Related]
4. Mammaglobin-A is a tumor-associated antigen in human breast carcinoma.
Tanaka Y; Amos KD; Fleming TP; Eberlein TJ; Goedegebuure PS
Surgery; 2003 Jan; 133(1):74-80. PubMed ID: 12563241
[TBL] [Abstract][Full Text] [Related]
5. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy.
Marcu A; Bichmann L; Kuchenbecker L; Kowalewski DJ; Freudenmann LK; Backert L; Mühlenbruch L; Szolek A; Lübke M; Wagner P; Engler T; Matovina S; Wang J; Hauri-Hohl M; Martin R; Kapolou K; Walz JS; Velz J; Moch H; Regli L; Silginer M; Weller M; Löffler MW; Erhard F; Schlosser A; Kohlbacher O; Stevanović S; Rammensee HG; Neidert MC
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858848
[TBL] [Abstract][Full Text] [Related]
6. Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution.
Bownds S; Tong-On P; Rosenberg SA; Parkhurst M
J Immunother; 2001; 24(1):1-9. PubMed ID: 11211143
[TBL] [Abstract][Full Text] [Related]
7. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
[TBL] [Abstract][Full Text] [Related]
8. Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer.
Matsueda S; Kobayashi K; Nonaka Y; Noguchi M; Itoh K; Harada M
Cancer Immunol Immunother; 2004 Jun; 53(6):479-89. PubMed ID: 14634796
[TBL] [Abstract][Full Text] [Related]
9. Translating Immunopeptidomics to Immunotherapy-Decision-Making for Patient and Personalized Target Selection.
Fritsche J; Rakitsch B; Hoffgaard F; Römer M; Schuster H; Kowalewski DJ; Priemer M; Stos-Zweifel V; Hörzer H; Satelli A; Sonntag A; Goldfinger V; Song C; Mahr A; Ott M; Schoor O; Weinschenk T
Proteomics; 2018 Jun; 18(12):e1700284. PubMed ID: 29505699
[TBL] [Abstract][Full Text] [Related]
10. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.
Jäger E; Chen YT; Drijfhout JW; Karbach J; Ringhoffer M; Jäger D; Arand M; Wada H; Noguchi Y; Stockert E; Old LJ; Knuth A
J Exp Med; 1998 Jan; 187(2):265-70. PubMed ID: 9432985
[TBL] [Abstract][Full Text] [Related]
12. Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.
Liu L; Wang Y; Miao L; Liu Q; Musetti S; Li J; Huang L
Mol Ther; 2018 Jan; 26(1):45-55. PubMed ID: 29258739
[TBL] [Abstract][Full Text] [Related]
13. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ
Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600
[TBL] [Abstract][Full Text] [Related]
14. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
Harao M; Hirata S; Irie A; Senju S; Nakatsura T; Komori H; Ikuta Y; Yokomine K; Imai K; Inoue M; Harada K; Mori T; Tsunoda T; Nakatsuru S; Daigo Y; Nomori H; Nakamura Y; Baba H; Nishimura Y
Int J Cancer; 2008 Dec; 123(11):2616-25. PubMed ID: 18770861
[TBL] [Abstract][Full Text] [Related]
15. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.
González FE; Ramírez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Salazar-Onfray F
Immunobiology; 2014 Mar; 219(3):189-97. PubMed ID: 24192537
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tsunoda T; Nakatsuru S; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
Clin Cancer Res; 2008 Oct; 14(20):6487-95. PubMed ID: 18927288
[TBL] [Abstract][Full Text] [Related]
17. CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.
Zhou R; Yazdanifar M; Roy LD; Whilding LM; Gavrill A; Maher J; Mukherjee P
Front Immunol; 2019; 10():1149. PubMed ID: 31178870
[TBL] [Abstract][Full Text] [Related]
18. In vivo evidence that peptide vaccination can induce HLA-DR-restricted CD4+ T cells reactive to a class I tumor peptide.
Harada M; Gohara R; Matsueda S; Muto A; Oda T; Iwamoto Y; Itoh K
J Immunol; 2004 Feb; 172(4):2659-67. PubMed ID: 14764741
[TBL] [Abstract][Full Text] [Related]
19. SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity.
Park J; Talukder AH; Lim SA; Kim K; Pan K; Melendez B; Bradley SD; Jackson KR; Khalili JS; Wang J; Creasy C; Pan BF; Woodman SE; Bernatchez C; Hawke D; Hwu P; Lee KM; Roszik J; Lizée G; Yee C
Cancer Immunol Res; 2017 Aug; 5(8):618-629. PubMed ID: 28630054
[TBL] [Abstract][Full Text] [Related]
20. Synthetic tumor-specific antigenic peptides with a strong affinity to HLA-A2 elicit anti-breast cancer immune response through activating CD8
Shi W; Qiu Q; Tong Z; Guo W; Zou F; Feng Z; Wang Y; Huang W; Qian H
Eur J Med Chem; 2020 Mar; 189():112051. PubMed ID: 31968280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
